venBio Partners LLC Purchases Shares of 5,266,697 Parabilis Medicines, Inc. $PBLS

Posted by Geri Gentry on Aug 28th, 2026

venBio Partners LLC purchased a new position in shares of Parabilis Medicines, Inc. (NASDAQ:PBLS – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,266,697 shares of the company’s stock, valued at approximately $144,149,497,000. Parabilis Medicines accounts for approximately 27.8% of venBio Partners LLC’s investment portfolio, making the stock its 2nd biggest holding. venBio Partners LLC owned approximately 4.46% of Parabilis Medicines at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. ARCH Venture Management LLC purchased a new position in shares of Parabilis Medicines during the 2nd quarter worth about $175,517,789,000. Alphabet Inc. purchased a new stake in Parabilis Medicines in the second quarter valued at approximately $134,647,000. Jupiter Topco LLC purchased a new stake in Parabilis Medicines in the second quarter valued at approximately $62,710,000. General Catalyst Group Management LLC purchased a new stake in Parabilis Medicines in the second quarter valued at approximately $43,818,000. Finally, ICONIQ Capital LLC acquired a new position in Parabilis Medicines during the second quarter worth approximately $9,580,000.

Insider Buying and Selling

In related news, Director Alan Sebulsky acquired 9,065 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was bought at an average cost of $26.49 per share, with a total value of $240,131.85. Following the acquisition, the director directly owned 30,000 shares in the company, valued at approximately $794,700. The trade was a 43.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Guy Levy purchased 500,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the purchase, the insider directly owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. This represents a 94.88% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 530,000 shares of company stock valued at $10,723,528 in the last three months.

Parabilis Medicines Stock Performance

NASDAQ PBLS opened at $39.29 on Friday. The stock’s fifty day moving average price is $32.64. Parabilis Medicines, Inc. has a 52 week low of $24.51 and a 52 week high of $41.49.

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $0.15 million during the quarter. As a group, equities research analysts anticipate that Parabilis Medicines, Inc. will post -2.05 earnings per share for the current year.

Analyst Ratings Changes

PBLS has been the subject of several research reports. Evercore started coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set an “outperform” rating for the company. Leerink Partners started coverage on Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating and a $40.00 target price on the stock. Bank of America initiated coverage on Parabilis Medicines in a report on Monday, July 6th. They issued a “buy” rating and a $45.00 target price on the stock. Zacks Research raised Parabilis Medicines to a “hold” rating in a research report on Tuesday, July 7th. Finally, Guggenheim initiated coverage on Parabilis Medicines in a research note on Monday, July 6th. They set a “buy” rating and a $40.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Parabilis Medicines has an average rating of “Buy” and a consensus price target of $41.67.

Get Our Latest Stock Report on PBLS

About Parabilis Medicines

(Free Report)

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.